988368
Fri, Apr 4, 2025
Volume 17, Issue 4 (December 2019)
Iranian Rehabilitation Journal 2019, 17(4): 359-368 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sabaghi M, Sadighi G, Khodaei Ardakani M R, Dieji B, Nowrouzi M, Aghaye Rashti M et al . Effects of Metformin on Weight Loss and Metabolic Control in Obese Patients With Schizophrenia and Schizoaffective Disorder: A Randomized Double-Blind Controlled Clinical Trial. Iranian Rehabilitation Journal 2019; 17 (4) :359-368
URL: http://irj.uswr.ac.ir/article-1-1019-en.html
URL: http://irj.uswr.ac.ir/article-1-1019-en.html
Mahboubeh Sabaghi1 
, Gita Sadighi *1 , Mohammad Reza Khodaei Ardakani1 , Bahman Dieji1 , Mehdi Nowrouzi2 , Maryam Aghaye Rashti3 , Sasan Zandi Esfahan4
, Gita Sadighi *1 , Mohammad Reza Khodaei Ardakani1 , Bahman Dieji1 , Mehdi Nowrouzi2 , Maryam Aghaye Rashti3 , Sasan Zandi Esfahan4
1- Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
2- Department of Statistics, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
3- Department of Statistics, Shahid Beheshti University, Tehran, Iran.
4- Department of Nursing and Midwifery, Najafabad Branch, Islamic Azad University, Isfahan, Iran.
2- Department of Statistics, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
3- Department of Statistics, Shahid Beheshti University, Tehran, Iran.
4- Department of Nursing and Midwifery, Najafabad Branch, Islamic Azad University, Isfahan, Iran.
Abstract: (4609 Views)
Objectives: The effect of metformin on weight changes and some metabolic parameters in patients with schizophrenia and schizoaffective disorder was investigated in this study.
Methods: As a randomized double-blind controlled clinical trial, this study was performed from 2018 to 2019. A total of 66 obese patients (BMI≥27) with schizophrenia and schizoaffective disorder, hospitalized in the departments of Razi Psychiatric Hospital, entered the study; then, they were randomly divided into intervention and control groups after completing the informed consent form. The patients received metformin or placebo for 12 weeks. The dose of metformin was gradually increased and in case of a patient’s tolerance, was prescribed up to 500 mg twice daily. During the study, all patients received their previous therapies. The variables included BMI, weight, waist circumference, lipid profile, and fasting blood glucose, which were studied at the beginning of the study and at weeks 4, 8, and, 12. The data were analyzed, using a post hoc test by SPSS software.
Results: The results showed a significant decrease in weight (3.5 kg) and BMI (1.30) at the end of the week 12, and there was a significant reduction in waist circumference (5.9 cm) at the end of the week 8 compared to the placebo group (P<0.05). Moreover, metformin had no significant effect on fasting blood glucose and lipid profile in comparison with the placebo group.
Discussion: Based on the findings of this study, by reducing the weight, waist circumference, and BMI, metformin can have a significant role in decreasing the complications of obesity and metabolic disorders in patients with schizophrenia and schizoaffective disorder. Therefore, given that the complications of metformin are low and transient, it can be recommended as a safe and tolerable drug in obese patients with schizophrenia and schizoaffective disorder.
Methods: As a randomized double-blind controlled clinical trial, this study was performed from 2018 to 2019. A total of 66 obese patients (BMI≥27) with schizophrenia and schizoaffective disorder, hospitalized in the departments of Razi Psychiatric Hospital, entered the study; then, they were randomly divided into intervention and control groups after completing the informed consent form. The patients received metformin or placebo for 12 weeks. The dose of metformin was gradually increased and in case of a patient’s tolerance, was prescribed up to 500 mg twice daily. During the study, all patients received their previous therapies. The variables included BMI, weight, waist circumference, lipid profile, and fasting blood glucose, which were studied at the beginning of the study and at weeks 4, 8, and, 12. The data were analyzed, using a post hoc test by SPSS software.
Results: The results showed a significant decrease in weight (3.5 kg) and BMI (1.30) at the end of the week 12, and there was a significant reduction in waist circumference (5.9 cm) at the end of the week 8 compared to the placebo group (P<0.05). Moreover, metformin had no significant effect on fasting blood glucose and lipid profile in comparison with the placebo group.
Discussion: Based on the findings of this study, by reducing the weight, waist circumference, and BMI, metformin can have a significant role in decreasing the complications of obesity and metabolic disorders in patients with schizophrenia and schizoaffective disorder. Therefore, given that the complications of metformin are low and transient, it can be recommended as a safe and tolerable drug in obese patients with schizophrenia and schizoaffective disorder.
Article type: Original Research Articles |
Subject:
Psychiatry
Received: 2019/05/1 | Accepted: 2019/08/24 | Published: 2019/12/29
Received: 2019/05/1 | Accepted: 2019/08/24 | Published: 2019/12/29
Send email to the article author
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
